IRS-1 HSV C134
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IRS-1 HSV C134, covering 2025-08-06 to 2025-08-06. Get the full timeline:
Most recent: Clinical Trial Update: A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma [Phase 1]